Buy Tirzepatide – Premium GIP/GLP-1 Receptor Agonist Research Peptide - Buy Tirzepatide (LY3298176) – Dual GIP/GLP-1 Receptor Agonist for Metabolic Research

Tirzepatide is a first-in-class, unimolecular dual receptor agonist that simultaneously targets the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors . This 39-amino acid synthetic peptide is conjugated to a C20 fatty diacid moiety for extended half-life, enabling once-weekly research protocols . Tirzepatide represents a significant advancement over selective GLP-1 receptor agonists, demonstrating superior glucose control and weight reduction in preclinical and clinical studies . This research-grade peptide is strictly for laboratory investigation and is not intended for human consumption.

Key Factual Details

Mechanism of Action & Research Applications

Dual Receptor Agonism

Tirzepatide selectively binds and activates both GIP and GLP-1 receptors, integrating complementary metabolic pathways . GLP-1 receptor activation enhances glucose-dependent insulin secretion, delays gastric emptying, suppresses appetite, and reduces glucagon production. GIP receptor activation contributes additional insulinotropic effects and improves insulin sensitivity independent of body weight changes .

Research Applications:

• Glucose Metabolism Studies: Investigating dual incretin pathway mechanisms for glycemic control

• Obesity Research: Examining GIP/GLP-1-mediated satiety and energy regulation

• Metabolic Disorder Models: Exploring therapeutic potential for type 2 diabetes and metabolic syndrome

• Weight Management Research: Evaluating sustained weight reduction pathways

• Receptor Interaction Studies: Characterizing GIP and GLP-1 receptor binding dynamics

Research Parameters

All dosages are for in-vitro and preclinical research use only and are not intended for human consumption.

Research Dosing Regimen (Based on Clinical Data) :

• Starting dose: 2.5 mg once weekly 

• Titration: Increase by 2.5 mg increments at ≥4-week intervals

• Maintenance range: 5 mg, 10 mg, or 15 mg once weekly 

Pharmacokinetic Properties :

• Half-life: Mean of 5.4 days 

• Accumulation: 1.7-fold with multiple dosing

• Tmax: 8-72 hours post-administration 

• No dose adjustments required for renal impairment, hepatic impairment, body weight, sex, age, or race 

Clinical Efficacy (Comparative Studies) :

• Significant weight reduction in obesity models

• Unprecedented improvement in glycemic control 

• Superior outcomes versus selective GLP-1 receptor agonists 

Storage:

• Store lyophilized powder at -20°C

• Protect from light and moisture